S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
pixel
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
pixel
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
pixel
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
pixel
Log in
NASDAQ:PACB

Pacific Biosciences of California Price Target, Predictions & Analyst Ratings

$36.31
-2.27 (-5.88 %)
(As of 01/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$34.76
Now: $36.31
$39.30
50-Day Range
$18.00
MA: $27.33
$40.20
52-Week Range
$2.20
Now: $36.31
$41.65
Volume4.84 million shs
Average Volume6.18 million shs
Market Capitalization$6.54 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.32

Analyst Ratings

Pacific Biosciences of California (NASDAQ:PACB) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Pacific Biosciences of California in the last 12 months. Their average twelve-month price target is $23.00, predicting that the stock has a possible downside of 36.66%. The high price target for PACB is $45.00 and the low price target for PACB is $12.00. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
PACB Consensus Rating: BuyBuyBuyBuy
PACB Consensus Rating Score: 2.502.502.803.00
PACB Analyst Ratings: 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
PACB Consensus Price Target: $23.00$16.00$11.60$6.00
PACB Price Target Upside: 36.66% downside9.40% upside27.81% upside43.60% upside

Pacific Biosciences of California (NASDAQ:PACB) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Pacific Biosciences of California (NASDAQ:PACB) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/15/2021Piper SandlerBoost Price TargetNeutral$12.00 ➝ $20.00Medium
1/12/2021Cantor FitzgeraldBoost Price TargetReduce ➝ Overweight$25.00 ➝ $45.00Medium
11/4/2020Morgan StanleyBoost Price TargetEqual Weight$7.00 ➝ $12.00High
10/2/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$15.00Low
12/18/2019Piper Jaffray CompaniesReiterated RatingBuy$7.00Low
4/2/2019StephensDowngradeOverweight ➝ Equal Weight$4.50 ➝ $8.00Low
1/4/2019CowenDowngradeOutperform ➝ Market PerformLow
(Data available from 1/22/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.